Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar eXigy (81.74) Submitted: 9/5/2007 2:59:30 PM : Underperform Start Price: $8.80 IDRA Score: +82.92

Not a long-termie, because I'm not personally well into the stock and cannot tell whether they have something unique in their safes to take it out by Easter or not.But I can tell a stock with such stats and such current price is to go down.

Featured Broker Partners


Advertisement